Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCVAC/PCa in localized high-risk prostate cancer
NCT02107430Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Mar 2012
- Primary completion
- Sep 2013
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of stapuldencel in prostate cancer (PCa) (2 arms), sponsored by SOTIO Biotech. Primary endpoint: Number of Prostate Specific Antigen (PSA) failures at 5 years. Started Mar 2012; status: completed.
02
Drugs
stapuldencel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02107430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02107430.